Carboxypeptidase B1 in dialyzed chronic kidney disease patients

Abstract Carboxypeptidase B1 has long been known to be a pancreas-specific tissue enzyme. In this paper we focus on Carboxypeptidase B1 concentration measurement in dialyzed chronic kidney kidney disease patients and on the effect dialysis adequacy and regimen exert on its concentration. A total of...

Full description

Saved in:
Bibliographic Details
Main Authors: Matej Stančík, Marián Grendár, Marián Mokáň
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-88332-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823862351006269440
author Matej Stančík
Marián Grendár
Marián Mokáň
author_facet Matej Stančík
Marián Grendár
Marián Mokáň
author_sort Matej Stančík
collection DOAJ
description Abstract Carboxypeptidase B1 has long been known to be a pancreas-specific tissue enzyme. In this paper we focus on Carboxypeptidase B1 concentration measurement in dialyzed chronic kidney kidney disease patients and on the effect dialysis adequacy and regimen exert on its concentration. A total of 142 subjects were divided into control and target groups. In the target group two measurements of plasma Carboxypeptidase B1 one month apart were conducted with the use of Carboxypeptidase B1 ELISA kit. The mean Carboxypeptidase B1 concentration was significantly higher in the target arm compared to the control arm (77.60 ± 11.81 ng/mL and 1.22 ± 0.41 ng/mL, respectively; p < 0.001). Generalized linear mixed regression revealed that affiliation with the control arm was the only significant contributor of this finding. Linear mixed model regression revealed that dialysis regimen that represents number of dialyses per one week-long cycle is a significant predictor of Carboxypeptidase B1 concentration. Exploration of the estimated marginal means of Carboxypeptidase B1 revealed that the Carboxypeptidase B1 concentration was significantly higher among patients on twice per week dialysis regimen than among those treated with three dialysis sessions per week.
format Article
id doaj-art-e6d693e23cb14db18623a3778c01bc65
institution Kabale University
issn 2045-2322
language English
publishDate 2025-02-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-e6d693e23cb14db18623a3778c01bc652025-02-09T12:35:36ZengNature PortfolioScientific Reports2045-23222025-02-0115111010.1038/s41598-025-88332-6Carboxypeptidase B1 in dialyzed chronic kidney disease patientsMatej Stančík0Marián Grendár1Marián Mokáň2Department of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaLaboratory of Bioinformatics and Biostatistics, Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaDepartment of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaAbstract Carboxypeptidase B1 has long been known to be a pancreas-specific tissue enzyme. In this paper we focus on Carboxypeptidase B1 concentration measurement in dialyzed chronic kidney kidney disease patients and on the effect dialysis adequacy and regimen exert on its concentration. A total of 142 subjects were divided into control and target groups. In the target group two measurements of plasma Carboxypeptidase B1 one month apart were conducted with the use of Carboxypeptidase B1 ELISA kit. The mean Carboxypeptidase B1 concentration was significantly higher in the target arm compared to the control arm (77.60 ± 11.81 ng/mL and 1.22 ± 0.41 ng/mL, respectively; p < 0.001). Generalized linear mixed regression revealed that affiliation with the control arm was the only significant contributor of this finding. Linear mixed model regression revealed that dialysis regimen that represents number of dialyses per one week-long cycle is a significant predictor of Carboxypeptidase B1 concentration. Exploration of the estimated marginal means of Carboxypeptidase B1 revealed that the Carboxypeptidase B1 concentration was significantly higher among patients on twice per week dialysis regimen than among those treated with three dialysis sessions per week.https://doi.org/10.1038/s41598-025-88332-6Carboxypeptidase B1DialysisChronic kidney diseaseUremic soluteUremic toxin
spellingShingle Matej Stančík
Marián Grendár
Marián Mokáň
Carboxypeptidase B1 in dialyzed chronic kidney disease patients
Scientific Reports
Carboxypeptidase B1
Dialysis
Chronic kidney disease
Uremic solute
Uremic toxin
title Carboxypeptidase B1 in dialyzed chronic kidney disease patients
title_full Carboxypeptidase B1 in dialyzed chronic kidney disease patients
title_fullStr Carboxypeptidase B1 in dialyzed chronic kidney disease patients
title_full_unstemmed Carboxypeptidase B1 in dialyzed chronic kidney disease patients
title_short Carboxypeptidase B1 in dialyzed chronic kidney disease patients
title_sort carboxypeptidase b1 in dialyzed chronic kidney disease patients
topic Carboxypeptidase B1
Dialysis
Chronic kidney disease
Uremic solute
Uremic toxin
url https://doi.org/10.1038/s41598-025-88332-6
work_keys_str_mv AT matejstancik carboxypeptidaseb1indialyzedchronickidneydiseasepatients
AT mariangrendar carboxypeptidaseb1indialyzedchronickidneydiseasepatients
AT marianmokan carboxypeptidaseb1indialyzedchronickidneydiseasepatients